Authors: Katzenstein, DA Hughes, MD Albrecht, M Liou, SH Murphy, R Balfour, H Para, M Hammer, S

Citation: Da. Katzenstein et al., Virologic and CD4 cell response to zidovudine or zidovudine and lamivudinefollowing didanosine treatment of human immunodeficiency virus infection, AIDS RES H, 17(3), 2001, pp. 203-210

Authors: DeGruttola, V Dix, L D'Aquila, R Holder, D Phillips, A Ait-Khaled, M Baxter, J Clevenbergh, P Hammer, S Harrigan, R Katzenstein, D Lanier, R Miller, M Para, M Yerly, S Zolopa, A Murray, J Patick, A Miller, V Castillo, S Pedneault, L Mellors, J

Citation: V. Degruttola et al., The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan, ANTIVIR TH, 5(1), 2000, pp. 41-48

Authors: Katzenstein, DA Hughes, M Albrecht, M Hammer, S Para, M Murphy, R Valdez, H Haubrich, R Liou, S

Citation: Da. Katzenstein et al., Virologic and CD4(+) cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection, AIDS RES H, 16(11), 2000, pp. 1031-1037

Authors: Morse, GD Reichman, RC Fischl, MA Para, M Leedom, J Powderly, W Demeter, LM Resnick, L Bassiakos, Y Timpone, J Cox, S Batts, D

Citation: Gd. Morse et al., Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies, ANTIVIR RES, 45(1), 2000, pp. 47-58